Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Relapsed and Bortezomib Refractory Multiple Myeloma
View Full LandscapeTarget Indication
Relapsed and Bortezomib Refractory Multiple Myeloma
Clinical Trial
NCT01083602Last updated: 1/27/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Farydak
Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent. Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.
View on EMAInfluenza
Heart Transplantation
Non-alcoholic Fatty Liver Disease (NAFLD)
Meningococcal Meningitis
Axial Spondyloarthritis